Analysts Expect Seattle Genetics, Inc. (SGEN) Will Announce Earnings of -$0.46 Per Share
Equities analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings per share (EPS) of ($0.46) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Seattle Genetics’ earnings, with the lowest EPS estimate coming in at ($0.55) and the highest estimate coming in at ($0.38). Seattle Genetics reported earnings per share of ($0.39) in the same quarter last year, which would indicate a negative year-over-year growth rate of 17.9%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 8th.
According to Zacks, analysts expect that Seattle Genetics will report full year earnings of ($0.92) per share for the current financial year, with EPS estimates ranging from ($1.01) to ($0.84). For the next fiscal year, analysts forecast that the company will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.76) to ($0.09). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Seattle Genetics.
Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $135.29 million during the quarter, compared to analysts’ expectations of $112.76 million. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The company’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.23) EPS.
In other news, CFO Todd E. Simpson sold 39,385 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $60.91, for a total value of $2,398,940.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eric Dobmeier sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $58.25, for a total value of $2,038,750.00. The disclosure for this sale can be found here. Insiders have sold 157,210 shares of company stock valued at $9,273,250 in the last ninety days. 34.70% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP increased its position in Seattle Genetics by 116.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 1,428 shares during the period. Bristlecone Advisors LLC bought a new position in shares of Seattle Genetics during the 3rd quarter worth approximately $180,000. Virtu Financial LLC bought a new position in shares of Seattle Genetics during the 3rd quarter worth approximately $203,000. DRW Securities LLC bought a new position in shares of Seattle Genetics during the 2nd quarter worth approximately $207,000. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Seattle Genetics during the 3rd quarter worth approximately $208,000. 98.94% of the stock is owned by institutional investors.
Shares of Seattle Genetics (NASDAQ:SGEN) opened at $51.82 on Friday. Seattle Genetics has a 1 year low of $45.31 and a 1 year high of $71.32.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/15/analysts-expect-seattle-genetics-inc-sgen-will-announce-earnings-of-0-46-per-share.html.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.